Related Contributions

Lessons from Dimebon
MEMBERS' OPEN FORUM: for rapid-fire posting of your questions and comments.
Shehan De Silva, MJFF
17 Mar 2010
This month, one of the best potential hopes for treating Alzheimer’s disease failed in its first late-stage clinical trial. As a result of a 2008 study, Dimebon, an antihistamine drug approved ... 
Phosphorylation of a-synuclein at S87: Commentary on Paleologou et al. (2010)
POWs: Papers of the Week
Ayse Ulusoy, Lund, et al.
16 Mar 2010
The majority of a-synuclein within Lewy bodies (LB) in PD brains and related synucleinopathies is phosphorylated. Phosphorylation of the serine residue at position 129 (S129) has been found in ... 
tangles and Lewy bodies may be two sides of the same coin
Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo.
Thomas G Beach, Sun Health
12 Mar 2010
First, you have to realize that the clinical diagnosis of DLB is only about 50% accurate overall. This may be better in situations where the clinical syndrome of DLB is all there in spades but even ... 
Immunotherapy for Parkinson's disease: Mechanisms and pathways for human use
UNMC takes next step in developing Parkinson’s disease vaccine
Howard Gendelman, et al.
04 Mar 2010
The therapeutic approach is based on the notion that the inciting event that underlies the pathogenesis of Parkinson’s disease (PD) is the accumulation of aggregated proteins within neuronal ... 
DOPAL triggers alpha-synuclein aggregation
Alpha-synuclein Summit
William J. Burke, SLU
11 Feb 2010
Alpha-synuclein (AS) is a normal constituent of neurons. It  becomes toxic when it aggregates to form oligomers or larger aggregates. The movement disorder in Parkinson disease (PD) is due to ... 
Validating PD targets: FK506 binding proteins
POWs: Papers of the Week
Mark Frasier, MJFF
22 Feb 2010
Digging through the POWs, I found this interesting paper from Veerle Baekelandt's group describing the role of FK506 binding proteins (FKBPs) in alpha-synuclein accumulation and alpha-synuclein ... 
Responses: 1
Alpha-synuclein Summit Take-aways
Alpha-synuclein Summit
Michael Sierks, ASU
04 Mar 2010
1)      Alpha-synuclein is an important and validated therapeutic target for PD.  While this was generally accepted at the meeting, this statement is not so generally ... 
Validating PD targets: FK506 binding proteins
POWs: Papers of the Week
Veerle Baekelandt, KU Leuven
02 Mar 2010
I would like to give a response to Mark Frasier’s questions based on our recent paper in J. Neurosci. ... 
Synuclein Summit Take-aways
Alpha-synuclein Summit
Warren Hirst, Pfizer
26 Feb 2010
1) There is still a need for more research to better understand both the normal and pathological functions of alpha-synuclein.  This will allow for the development of novel therapeutics ... 
Synuclein Summit Take-aways
Alpha-synuclein Summit
Evangelia Emmanouilidou, BioAcademy
26 Feb 2010
1. There is an increasing interest for the development of alpha-synuclein-based imaging techniques, especially for ones targeted to specific species. However, it seems like much more work is needed ...